Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03029429
PHASE2

Theophylline Treatment for Pseudohypoparathyroidism

Sponsor: Vanderbilt University Medical Center

View on ClinicalTrials.gov

Summary

Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight loss, improve glucose tolerance and slow growth plate closure in children and young adults.

Official title: Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism

Key Details

Gender

All

Age Range

13 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

29

Start Date

2018-09-01

Completion Date

2026-12-01

Last Updated

2026-02-20

Healthy Volunteers

No

Interventions

DRUG

Theophylline

oral theophylline

DRUG

Placebos

oral placebo

Locations (1)

Ashley Shoemaker

Nashville, Tennessee, United States